Relation of statin use to the 5-year incidence and progression of age-related maculopathy

Arch Ophthalmol. 2003 Aug;121(8):1151-5. doi: 10.1001/archopht.121.8.1151.

Abstract

Objective: To examine the association of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) with the 5-year incidence of age-related maculopathy (ARM).

Design: Population-based cohort study. Participants included persons 48 to 91 years old examined March 1, 1993, through June 14, 1995, living in Beaver Dam, Wis (N = 3684), of whom 2780 participated in a follow-up 5 years later.

Methods: Standardized procedures were used for physical examinations, blood sample collection, and questionnaire administration. Age-related maculopathy was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed.

Main outcome measures: Incidence and progression of ARM was measured over the 5-year interval.

Results: While controlling for age and sex, statin use was not found to be associated with the 5-year incidence of early ARM (odds ratio [OR], 1.12; 95% confidence interval [CI], 0.47-2.67), progression of ARM (OR, 1.22; 95% CI, 0.54-2.76), or incidence of late ARM (OR, 0.41; 95% CI, 0.12-1.45).

Conclusions: These findings do not suggest an association between statin use and incident ARM over a 5-year period. Further investigation of these relationships in larger studies over a longer period is needed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression
  • Drug Utilization / statistics & numerical data*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Incidence
  • Macular Degeneration / epidemiology*
  • Macular Degeneration / physiopathology
  • Male
  • Middle Aged
  • Odds Ratio
  • Prevalence
  • Surveys and Questionnaires
  • Wisconsin / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors